pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

partner-therapeutics PRESS RELEASE ARCHIVE

Dec 15, 2022

Partner Therapeutics Announces Publication of a Retrospective Cohort Review of 15 LEUKINE Treated Patients with Pediatric Malignancies and Invasive Fungal Disease Refractory to Antifungal Therapy

Mar 29, 2022

Partner Therapeutics Announces Publication of Results from Pre-Clinical Study Evaluating Recombinant Murine GM-CSF in Mouse Models of Down Syndrome and Normal Aging

Feb 17, 2022

Partner Therapeutics Announces Contract with U.S. Department of Defense for Advanced Development of Leukine to Treat Sulfur Mustard Gas (HD) Exposure

Sep 20, 2021

BARDA and Partner Therapeutics foster a new partnership around their FDA-approved drug, Leukine to improve patient care for sepsis patients

May 19, 2021

Partner Therapeutics Announces Publication of Clinical Trial Results of Leukine (sargramostim) in Patients with Parkinson's Disease

Apr 29, 2021

Partner Therapeutics Initiates Patient Enrollment in Clinical Trial Evaluating Leukine (rhuGM-CSF, sargramostim) in High-risk Non-hospitalized COVID-19 Patients (SCOPE)

Mar 24, 2021

Partner Therapeutics Announces Publication of Clinical Trial Results Showing Significant Benefit with Use of Leukine (sargramostim) in Patients with Alzheimer's Disease

Mar 3, 2021

Partner Therapeutics Announces Partnership with SIRS Therapeutics and F4 Pharma to Explore Potential Uses for FX06 in Biodefense Applications

Feb 18, 2021

Partner Therapeutics Announces Publication of Two Studies Demonstrating Leukine Improves Survival in Acute Radiation Syndrome (ARS)

Sep 15, 2020

Partner Therapeutics (PTx) Announces the Appointment of Ed Rock as Chief Medical Officer

Sep 11, 2020

Partner Therapeutics Announces Start of Phase 3 Portion of Clinical Study of Leukine in Combination with Ipilumimab and Nivolumab in Front Line Treatment of Melanoma

Aug 25, 2020

Partner Therapeutics Initiates Patient Enrollment in U.S. Clinical Trial Evaluating Leukine (rhuGM-CSF, sargramostim) in COVID-19 Patients

Aug 4, 2020

Partner Therapeutics Announces $35 Million Contract with U.S. Department of Defense for Advanced Development and Emergency Use of Leukine (rhuGM-CSF) for COVID-19 Acute Hypoxemic Respiratory Failure (AHRF)

Jun 11, 2020

Partner Therapeutics Announces Initiation of Clinical Trial Evaluating Leukine in T Cell Replete HLA-mismatched Haploidentical Stem Cell Transplant

May 28, 2020

Partner Therapeutics Announces Initiation of Clinical Trial to Evaluate Leukine in Respiratory Illness in Patients with COVID-19 at Singapore General Hospital

Mar 24, 2020

Partner Therapeutics Announces Initiation of Clinical Trial to Evaluate Leukine in Patients with COVID-19 Associated Respiratory Illness

Nov 7, 2019

Partner Therapeutics (PTx) Announces the Appointment of John McManus as Chief Business Officer

Sep 19, 2019

Partner Therapeutics Receives Orphan Drug Designation for Leukine (sargramostim)

Nov 6, 2018

Partner Therapeutics Receives FDA Orphan Drug Designation for Leukine for the Treatment of Pulmonary Alveolar Proteinosis

Jun 6, 2018

Partner Therapeutics (PTx) Announces US FDA Approval of Leukine (sargramostim) for the Treatment of Acute Radiation Syndrome

May 24, 2018

Tanner Pharma Group Signs a Distribution Agreement for Partner Therapeutics’ Product, Leukine

Mar 7, 2018

Partner Therapeutics (PTx) Announces the Appointment of Ellen Hukkelhoven Ph.D. and Terry Gould to its Board of Directors

Feb 1, 2018

Partner Therapeutics (PTx) Acquires Leukine from Sanofi

Feb 1, 2018

Partner Therapeutics, Inc. (PTx) Closes $60 Million Financing

Google Analytics Alternative